Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project

European Heart Journal

Volumn 24, Issue 11, 2003, Pages 987-1003

  Conroy, R M ^a   Pyorala K ^b   Fitzgerald, A P ^a   Sans, S ^c   Menotti, A ^d   De Backer, G ^e   De Bacquer, D ^e   Ducimetiere P ^f   Jousilahti, P ^g   Keil, U ^h   Njolstad I ⁱ   Oganov, R G ^j   Thomsen, T ^k   Tunstall Pedoe, H ^l   Tverdal, A ^m   Wedel, H ⁿ   Whincup, P ^o   Witheimsen, L ⁿ   Graham, Ian M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c INSTITUT CATALÀ DE LA SALUT   (Spain)

^d Association for Cardiac Research   (Italy)

^e GHENT UNIVERSITY   (Belgium)

^f INSERM   (France)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ UNIVERSITY OF TROMSØ   (Norway)

^j NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^k GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^l UNIVERSITY OF DUNDEE   (United Kingdom)

^m NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

ⁿ UNIVERSITY OF GOTHENBURG   (Sweden)

^o ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BELGIUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DENMARK; DIABETES MELLITUS; FATALITY; FEMALE; FINLAND; FRANCE; GERMANY; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORWAY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; ROC CURVE; RUSSIAN FEDERATION; SMOKING; SPAIN; SWEDEN; UNITED KINGDOM;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETIC ANGIOPATHIES; EPIDEMIOLOGIC METHODS; EUROPE; HUMANS; MALE; MIDDLE AGED;

EID: 0038579421     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00114-3     Document Type: Article

References (60)

1. Pyörälä K, deBacker G, Graham I et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31.
2. Grundy SM, Balady GJ, Criqui MH et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-87.
3. Anonymous. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998;80(Suppl 2):S1-29.
4. Robson J, Feder G. Predicting and reducing cardiovascular risk. Heart 2001;85:487-8.
5. Pearson TA, Blair SN, Daniels SR et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atheroscierotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91.
6. Wood DA, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19:1434-503.
7. Jackson R. Guidelines on preventing cardiovascular disease in clinical practice. BMJ 2000;320:659-61.
8. Anderson KM, Wilson PW, Odell PM et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
9. Jackson R, Barham P, Bills J et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107-10.
10. D'Agostino RBS, Grundy S, Sullivan LM et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
11. Haq IU, Ramsay LE, Yeo WW et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999;81:40-6.
12. Pyörälä K. Assessment of coronary heart disease risk in populations with different levels of risk. Eur Heart J 2000; 21:348-50.
13. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21:365-70.
14. Thomsen TF, McGee D, Davidsen M et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002;31:817-22.
15. Hense HW, Schulte H, Löwel H et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany. Results from the MONICA Augsburg cohort and the PROCAM cohort. Eur Heart J 2003;In Press.
16. Dawber TR, Kannel W, Revotskie N et al. The epidemiology of coronary heart disease - the Framingham Enquiry. Proc Royal Soc Med 1962;55:265-71.
17. D'Agostino RB, Russell MW, Huse DM et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81.
18. Menotti A, Lanti M, Puddu PE et al. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000;84:238-44.
19. Vartiainen E, Jousilahti P, Alfthan G et al. Cardiovascular risk factor changes in Finland 1972-1997. Int J Epidemiol 2000;29:49-56.
20. Anonymous. Collaborative US-USSR study on the prevalence of dyslipoproteinemias and ischemic heart disease in American and Soviet populations. Prepared by the US-USSR Steering Committee for Problem Area 1: the pathogenesis of atherosclerosis. Am J Cardiol 1977;40:260-8.
21. Bjartveit K, Foss OP, Gjervig T et al. The cardiovascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl 1979;634:1-70.
22. Njølstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. Circulation 1996;93:450-6.
23. Shaper AG, Pocock SJ, Walker M et al. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981;283:179-86.
24. Tunstall-Pedoe H, Woodward M, Tavendale R et al. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 1997;315:722-9.
25. Schroll M, Jorgensen T, Ingerslev J. The Glostrup Population Studies 1964-1992. Dan Med Bull 1992;39:204-7.
26. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Göteborg Sweden. Eur Heart J 1986;7:279-88.
27. Anonymous. (The BIRNH Study Group). Regional differences in dietary habits, coronary risk factors and mortality rates in Belgium. 1. Design and methodology. Nutrition and health: an interuniversity study. Acta Cardiol 1984;39:285-92.
28. Keil U, Liese AD, Hense HW et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J 1984;19:1197-207.
29. Anonymous. (The RIFLE Research Group). Presentation of the RIFLE project risk factors and life expectancy. Eur J Epidemiol 1993;9:459-76.
30. Ducimetière P, Richard JL, Cambien F et al. Coronary heart disease in middle-aged Frenchmen. Comparisons between Paris Prospective Study, Seven Countries Study and Pooling Project. Lancet 1980;1:1346-50.
31. Sans Menéndez S, Tomás Abadal L, Domingo Salvany A et al. Estudio de prevención multifactorial de la cardiopatía isquémica. Intervención sobre factores de riesgo coronario en una población industrial. Resultados de los dos primeros años. Rev San Hig Publ 1981;55:555-70.
32. Rodés A, Sans S, Balañá LL et al. Recruitment methods and differences in early late and non-respondents in the first MONICA-Catalonia population survey. Rev Epidemiol Sante Publique 1990;38:447-53.
33. Sans Menéndez S. Ensayo randomizado de prevención multifactorial de la cardiopatia isquémica. PhD doctoral dissertation. Bellaterra: Publications of the Autonomous University of Barcelona. 1994.
34. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80.
35. Weissler AM. A perspective on standardizing the predictive power of noninvasive cardiovascular tests by likelihood ratio computation: 2. Clinical applications. Mayo Clin Proc 1999; 74:1072-87.
36. Lin LI-K. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68.
37. Lin LI-K. A note on the concordance correlation coefficient. Biometrics 2000;56:324-5.
38. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18:1231-48.
39. Dawber TR, Kannel WB, McNamara PM. The prediction of coronary heart disease. In: Moore SRJ, editor. Transactions of the Association of Life Insurance Medical Directors of America, Seventy-Second Annual Meeting, October 16, 1963, New York City. New York: Recording & Statistical Company; 1964, p. 70-105.
40. Wilson PF, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
41. Grundy SM, Pasternak R, Greenland P et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
42. Anonymous. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
43. Anonymous. Treatment and prevention of coronary heart disease by cholesterol lowering therapy: Consensus cholesterol, second revision. [In Dutch] Utrecht: CBO, 1998.
44. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 2001;22:919-25.
45. Marshall T, Rouse A. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ 2002;325:197.
46. Durrington PN, Prais H, Bhatnagar D et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet 1999;353:278-81.
47. Durrington PN, Prais H. Methods for the prediction of coronary heart disease risk. Heart 2001;85:489-90.
48. Smith SCJ, Blair SN, Criqui MH et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92:2-4.
49. Wilhelmsen L, Pyörälä K, Wedel H et al. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J 2001;22:1119-27.
50. Grover SA, Paquet S, Levinton C et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs. secondary prevention [published erratum appears in Arch Intern Med Jun 8; 158(11):1228]. Arch Intern Med 1998;158:655-62.
51. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
52. Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 1998;21:539-45.
53. Stevens RJ, Kothari V, Adler AI et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9.
54. Anonymous. National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. N Z Med J 1996;109:224-31.
55. Hinsorani AD, Vallance P. A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 1999;318:101-5.
56. Zambanini A, Smith MR, Feher MD. Prediction of cardiovascular risk. Program is not suitable for diabetic patients. BMJ 1999;318:1418 author reply 1419.
57. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
58. Anonymous. Report of a WHO consultation: definition, diagnosis and classification of diabetes mellitus. (WHO/NCD/ NCS/99.2). Geneva: World Health Organization, 1999.
59. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44(Suppl 2):S54-64.
60. Kothari V, Stevens RJ, Adler AI et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81.